| Subject: | FDA Announces Safety Factor Related to Protonix IV Preparation for Administration |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 6 Oct 2004 - 10:00 am |
| The FDA and Wyeth Pharmaceuticals have reported to healthcare professionals the potential for glass vial breakage during the preparation of Protonix IV. Protonix I.V. (Pantoprazole Sodium) is prescribed for patients for the short-term treatment (seven to 10 days) of gastroesophageal reflux disease (GERD) as an alternative to oral therapy (for those patients. Protonix is in a drug class known as proton pump inhibitors (PPI); PPIs are frequently replacing treatment with IV H2 antagonists to... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
